Speech Title: Novel Tools in the Active Surveillance Pathway
Dr. Laurence Klotz was educated at the University of Toronto, Ontario, where in 1977 he obtained his MD. Dr. Klotz completed his residency at the University of Toronto in 1983. Subsequently, he was a Fellow in Uro-Oncology and Tumor Biology at the Memorial Sloan Kettering Cancer Center in New York, completing it in 1985.
Dr. Klotz then returned to Sunnybrook Health Sciences Centre in Toronto. He is an Associate Scientist at the Sunnybrook Research Institute, the past Chief of Urology, Professor of Surgery at the University of Toronto, and holds the Sunnybrook Chair of Prostate Cancer Research.
Dr. Klotz is a widely published uro-oncologist (470 peer review publications, 6 books). His basic research interests have included research in the role of micronutrients and diet in prostate cancer prevention, and translational research in biomarkers and imaging. His research lab has been active for 30 years, producing several patents and a biotech company. His clinical research interests have been in the areas of active surveillance, image guided therapy, molecular biomarkers, and androgen receptor targeted therapy. He has led numerous randomized trials in prostate cancer.
Active surveillance was a concept pioneered under Dr. Klotz’s leadership. He led the team at Sunnybrook who was the first to implement an approach to patients with low risk prostate cancer based on conservative management, with selective intervention for those patients who were diagnosed as higher risk over time. He coined the term ‘active surveillance’, and was responsible for promoting its acceptance by urological and radiation oncology communities worldwide. His drive to reduce the overtreatment, morbidity, and mortality of prostate cancer has led to over a hundred papers on this subject and numerous national and international invitations as a guest lecturer and visiting professor.
In addition to his basic and clinical research endeavors, Dr. Klotz has initiated and participated in many professional organizations and societies. In 1994, he founded the Canadian Journal of Urology, which was the officially endorsed journal of the Canadian Urological Association from 1992 to 2004. In 2005 he founded the Canadian Urology Association Journal in conjunction with the CUA, was Editor in Chief until 2010, and currently is the CUAJ Editor Emeritus. He has been Associate Editor of the Journal of Urology (for Prostate Cancer) since 2013.
Dr. Klotz established and chaired the Canadian Urology Consortium (CURC), a clinical research network, in 2000 and the World Urologic Oncology Federation (WUOF), which brought 20 Uro Oncology Societies together under one umbrella in 2002.
Dr. Klotz was awarded the Queen’s Jubilee Medal in 2013 for meritorious public service, and the University of Toronto Department of Surgery Lister Prize for outstanding research contributions and the Society of Urologic Oncology Medal in 2014.
In 2015 he received Canada’s highest civilian award, the Order of Canada, and the Harold Warwick Prize from the Canadian Cancer Society for international contributions to cancer control. The AUA presented him the Richard Williams Award for outstanding contributions in urologic oncology in 2016. He has received Lifetime Achievement Awards from the University of Toronto in 2017 and the Canadian Urological Association in 2019. He received the Huggins medal from the SUO in 2019.
Dr. Klotz is married to Ursula, and has 2 children, Alex, a professor of physics at California State in Los Angeles, and Betsy, a recreational therapist. He founded ‘The Void’, an all-Urology Band in which he plays piano. He has never received any awards for his tennis or ice hockey performance, both of which he plays frequently.